Is this you?
Request access for Progressive Medical Research with your @progressivemedicalresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Progressive Medical Research
Unclaimed profileIndependent Site · Port Orange, Florida · ~1 sites
Intera lens
ICP 5Lift (cardio sample) 0.23Recruit soph 0.43
Quality Scorecard (1–100)
Overall77Recruit70Ops79Sponsor84Ther76
Performance (observed)
Historical trials
361
Completed
238
Terminated/Withdrawn
43
Completion rate
85%
Active now
72
Phase 2
134
Phase 3
189
Realized enrollment
461,774
First study year
2001
Years active
25
Match confidence
high
Enrollment velocity (inf)
18,471
Therapeutic
Areas
Osteoarthritis, COPD, Weight Loss, Alzheimer's Disease, High Triglycerides, Hypertension, Cardiovascular, Fatty Liver, Alzheimer's Prevention
Specialties
Phase I-III: Alzheimer's, COPD, Weight Loss, Hypertension, Triglycerides, Cardiac, Fatty Liver
Breadth (conditions)
256
Languages
English + Spanish (detected)
States
Florida
Recruitment (web observed)
Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Limited (featured in Life Sciences Review)
Capability notes
Strong - 10+ years experience, patient-focused innovation, recognized excellence (Life Sciences Review cover)
Relationships
Sponsors
Eli Lilly and Company; Pfizer; AbbVie; Janssen Research & Development, LLC; Incyte Corporation; Hoffmann-La Roche
CROs
Covance; IQVIA Pty Ltd; Medpace, Inc.; PPD Development, LP; PRA Health Sciences; Parexel
Partnerships
Alzheimer's Association
Owner / parent
Unknown
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
clinicaltrials@kardigan.bio
Tech & DCT
Builds tech
Unknown
Home visits
N - on-site facility focus
DCT / decentralized
N - dedicated on-site facility model
Tech stack
Not specified
Recruiting visible
Y
Notes
Single independent site in Port Orange. 9 active recruiting cardiometabolic trials per ClinicalTrials.gov. 10+ years experience, Phase I-III capabilities. Recognized excellence in trial execution and patient-focused innovation (Life Sciences Review). Single location limits expansion. No visible modern technology or AI adoption.
Recommendation features (sample indication)
Ind fit 0.40Liftability 0.23Overall77
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.